fake tirzepatide Weight-loss drugs could see a shortage until 2025, makers predict June 25, 2024: WHO alert

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two distinct indications: treatment of type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity

Sources American College of Nutrition (2023) American Academy of Family Physicians (2022) National Institutes of Health (NIH, 2023) Interested in This Treatment

Tirzepatide is not a replacement for these fundamentals but rather a tool that makes sustainable choices more achievable by addressing the metabolic dysfunction that tamoxifen and other cancer treatments create

To learn about planning treatments, check out how often NAD IV therapy

Blood pressure changes and hydration levels have an influence

Save your receipts